Replimune Group Inc REPL

$17.61 +0.22 (1.27%)

Valuation

Market cap
1,669,428,000
Revenue TTM
$0
Net income TTM
$-313,940,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.80

Trading

Volume
3,853,600
Avg volume
2,289,594
Day's range
$16.64 – $18.27
Shares out
94,800,000
Stochastic %K
91%
Beta
0.93
Analysts
Moderate Buy
Price target
$22.33

Price

Company profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1...

Show more

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 222 9600
Website
https://www.replimune.com
Address
500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, United States

Latest news

Stocktwits

Merlintrader Oct 31, 11:48 PM
$REPL closed the week at $17.61 (+53.7% w/w, +1.3% Friday), above the 50-day SMA ($13.58) and above the 200-day ($9.29). RSI14 75.1. Support $10.67, resistance $18.27 (20-day range, top). New hub updated: https://www.merlintrader.com/replimune-group-stock-hub/
0 replies
Robert345 Oct 31, 1:19 PM
$REPL
0 replies
JFais Oct 31, 11:26 AM
$OBX (NP) Interesting SITC abstract coming up: OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: Pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen Slides compare 67% ORR in median 2 prior lines of therapy vs 31% for $IOVA Amtagvi pivotal trial (not a fair comparison though, as real-world data in 2 or fewer prior lines yielded 52% ORR) Favorable safety, no DLTs, treatment-related mortality or ICU stay Phase 1 NSCLC data 1H 27 En fin, on my DD list as well (not a zero sum game) $REPL $IMTX
0 replies
Valueforall Oct 30, 6:14 PM
$IOVA friendly reminder of $REPL I invested heavy in this at $2 when it got 2nd denial. Sum of the parts valuation and combo with BMy made me see that this was going to get approved and or bought. Similar platform like IOVA and minus Baker bros. This is a hiccup. Reminder why you have to actively trade a core and sell rips as the volatility upward is massive
0 replies
TapeReader007 Oct 30, 2:01 PM
$IOVA KRAS population alone will be 5 times more than $REPL TAM. So Iovance Lung narrow indication alone should trade at 8 billion valuation, 8 times of revenue without Amtagvi. So don't be scared but don't rush to buy all your lots right away.
0 replies
topstockalerts Oct 30, 12:37 AM
$REPL there’s a certain stubbornness to this strength.
0 replies
DRAM27 Oct 29, 11:32 PM
$REPL How much are you down with that strategy? You'd be up more than 50% if you bought when I was pounding the table. We will not see anything close to $10 for the rest of the year! 🚀🚀🚀
1 replies
Gluteshevaa Oct 29, 8:05 PM
$REPL short it to 0
0 replies